Boyle, William J.

Osteoclast differentiation and activation

Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature

Bone Metabolism and DiseasesBone health and osteoporosis research

Cited by 6,670

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.

Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature

Bone Metabolism and DiseasesT-cell and B-cell Immunology

Cited by 3,351

Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.

Kong, Y.-Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., et al. (1999) · Nature

Bone Metabolism and DiseasesRheumatoid Arthritis Research and Therapies

Cited by 1,856

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.

Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences

Bone Metabolism and DiseasesOsteomyelitis and Bone Disorders Research

Cited by 1,636

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis, and regulation of bone mass and calcium metabolism.

Li, J., Sarosi, I., Yan, X.-Q., Morony, S., Capparelli, C., Tan, H.-L., McCabe, S., Elliott, R., Scully, S., Van, G., et al. (2000) · Proceedings of the National Academy of Sciences

Bone Metabolism and DiseasesOsteomyelitis and Bone Disorders Research

Cited by 1,119

Oncogene jun encodes a sequence-specific trans- activator similar to AP-1

Angel, P., Allegretto, E. A., Okino, S. T., Hattori, K., Boyle, W. J., Hunter, T., & Karin, M. (1988) · Nature

Genomics and Chromatin DynamicsProtein Kinase Regulation and GTPase Signaling

Cited by 907

Role of RANK ligand in mediating increased bone resorption in early postmenopausal women

Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L. (2003) · Journal of Clinical Investigation

Bone Metabolism and DiseasesBone health and osteoporosis research

Cited by 825

The osteoclast differentiation factor osteoprotegerin ligand is essential for mammary gland development.

Fata, J. E., Kong, Y.-Y., Li, J., Sasaki, T., Irie-Sasaki, J., Moorehead, R. A., Elliott, R., Scully, S., Voura, E. B., Lacey, D. L., et al. (2000) · Cell

Bone Metabolism and DiseasesEstrogen and related hormone effects

Cited by 756

The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.

Burgess, T. L., Qian, Y.-X., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., Kelley, M., Hsu, H., Boyle, W. J., Dunstan, C. R., et al. (1999) · The Journal of Cell Biology

Bone Metabolism and DiseasesBone and Dental Protein Studies

Cited by 689

Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis.

Min, H., Morony, S., Sarosi, I., Dunstan, C. R., Capparelli, C., Scully, S., Van, G., Kaufman, S., Kostenuik, P. J., Lacey, D. L., et al. (2000) · The Journal of Experimental Medicine

Bone Metabolism and DiseasesBone health and osteoporosis research

Cited by 550

Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.

Lacey, D. L., Tan, H. L., Lu, J., Kaufman, S., Van, G., Qiu, W., Rattan, A., Scully, S., Fletcher, F., Juan, T., et al. (2000) · The American Journal of Pathology

Bone Metabolism and DiseasesCell death mechanisms and regulation

Cited by 391